Professor Nigel Jamieson

Professor (Clinical Research Garscube)

School of Medicine, Dentistry & Nursing, Level 2, New Lister Building, Glasgow Royal Infirmary, Glasgow, G31 2ER

Biography

Nigel Jamieson is a Clinical Senior Lecturer within the Institute of Cancer Sciences and an Honorary HPB surgeon at Glasgow Royal Infirmary. He completed his undergraduate medical degree at the University of Glasgow when his interest in pancreatic cancer research began. He subsequently undertook a PhD funded by the Chief Scientist Office investigating gene expression signatures in pancreatic adenocarcinoma at the Beatson Institute. After completing his surgical training including observership periods at Johns Hopkins, Baltimore and Memorial Sloan Kettering Cancer Center, New York he undertook an international fellowship year of pancreas and liver surgery in Royal North Shore Hospital, Sydney, Australia where he gained significant experience in post-neoadjuvant therapy pancreatic resections. Grants from the Academy of Sciences and Pancreatic Cancer UK maintained his research output during his surgical training. He was recently awarded a Clinician Scientist Fellowship by Cancer Research UK and upon returning to Glasgow was awarded a Lord Kelvin and Adam Smith Leadership Fellowship from the University of Glasgow.

He has contributed to over 70 peer reviewed publications and with an active role in the development and management of the Precision-Panc platform, his primary research interest now focusses upon the interaction between the genomic landscape, the immune microenvironment and chemotherapy in patients with pancreatic cancer. Specifically, he will look to develop combination therapeutic strategies that target Immune evasion in pancreatic cancer.

Research interests

Research groups

Cancer Evolution in Time & Space

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2006 | 2005 | 2004 | 2003

Number of items: 123.

2024

McGuigan, M.-C., Hadjicosti, R., Cameron, A. J. , Coats, M., Chang, D. , Dickson, E. J., Holroyd, D., McKay, C. J. and Jamieson, N. B. (2024) The surveillance strategy for Intraductal Pancreatic Mucinous Neoplasms: Criteria for discontinuation. Annals of Surgery, (Accepted for Publication)

Lucocq, J. et al. (2024) Precursor epithelial subtypes of adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMN): clinicopathological features, recurrence and response to adjuvant chemotherapy. Annals of Surgical Oncology, 31(10), pp. 7023-7032. (doi: 10.1245/s10434-024-15677-z) (PMID:38961040)

McKenzie, M., Lian, G.-Y., Pennel, K. A.F., Quinn, J. A. , Jamieson, N. B. and Edwards, J. (2024) NFκB signalling in colorectal cancer: examining the central dogma of IKKα and IKKβ signalling. Heliyon, 10(12), e32904. (doi: 10.1016/j.heliyon.2024.e32904) (PMID:38975078) (PMCID:PMC11226910)

Boey, A., Bryce, A. , Dickson, E., Coats, M., McKay, C., Jamieson, N. , Chang, D. , Holroyd, D. and Dreyer, S. (2024) The Impact of Pre-operative Indeterminate Lung Nodules in the Surgical Management of Pancreatic Ductal Adenocarcinoma. 16th World Congress of the International Hepato-Pancreato-Biliary Association, Cape Town, South Africa, 15-18 May 2024. S148. (doi: 10.1016/j.hpb.2024.03.269)

Lucocq, J. et al. (2024) Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study. British Journal of Surgery, 111(4), znae100. (doi: 10.1093/bjs/znae100) (PMID:38659247)

Pennel, K. A.F. et al. (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43, 64. (doi: 10.1186/s13046-024-02958-4)

McGovern, J., Mackay, C., Freireich, R., Golder, A. M. , Dolan, R. D. , Horgan, P. G. , Holroyd, D., Jamieson, N. B. and McMillan, D. C. (2024) The relationship between liver volume, clinicopathological characteristics and survival in patients undergoing resection with curative intent for non-metastatic colonic cancer. Tomography, 10(3), pp. 349-359. (doi: 10.3390/tomography10030027) (PMID:38535769) (PMCID:PMC10974240)

Dreyer, S., Bryce, A. , Australian Pancreatic Cancer Genome Initiative, , Biankin, A. , Jamieson, N. and Chang, D. (2024) The clinical and molecular landscape of early onset pancreatic cancer. 42nd Congress of the European Society of Surgical Oncology, Florence, Italy, 25-27 Oct 2023. (doi: 10.1016/j.ejso.2023.107348)

Robertson, F. P., Cameron, A. , Spiers, H. V.M., Joseph, N., Taylor, E., Ratnayake, B., Jamieson, N. B. and Pandanaboyana, S. (2024) Evidence for molecular subtyping in pancreatic ductal adenocarcinoma: A systematic review. HPB, (doi: 10.1016/j.hpb.2024.02.001) (PMID:38401998)

Shamis, S. A. K., Savioli, F., Ammar, A. , Al-Badran, S. S.F., Hatthakarnkul, P., Leslie, H. , Mallon, E., Jamieson, N. B. , McMillan, D. C. and Edwards, J. (2024) Spatial transcriptomic analysis of tumour with high and low CAIX expression in TNBC tissue samples using GeoMx™ RNA assay. Histology and Histopathology: Cellular and Molecular Biology, 39, pp. 177-200. (doi: 10.14670/HH-18-655) (PMID:37681672)

2023

Lucocq, J. et al. (2023) Risk of recurrence after surgical resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia (IPMN) with patterns of distribution and treatment. Annals of Surgery, 280(1), pp. 126-135. (doi: 10.1097/sla.0000000000006144) (PMID:37873663)

O’Rourke, C. J. et al. (2023) Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy. Gut, (doi: 10.1136/gutjnl-2023-330748) (PMID:37758326) (Early Online Publication)

Haddad, T. S. et al. (2023) Pseudobudding: ruptured glands do not represent true tumor buds. Journal of Pathology, 261(1), pp. 19-27. (doi: 10.1002/path.6146) (PMID:37403270)

Pennel, K., Morrow, E., Hatthakarnkul, P., Leslie, H. , Mallon, E., Andersen, D., Jamieson, N. , McMillan, D. , Roseweir, A. and Edwards, J. (2023) High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients. Cancer Medicine, 12(12), pp. 13225-13240. (doi: 10.1002/cam4.6014) (PMID:37199043) (PMCID:PMC10315752)

Sykes, R. A. et al. (2023) Vascular mechanisms of post-COVID-19 conditions: rho-kinase is a novel target for therapy. European Heart Journal: Cardiovascular Pharmacotherapy, 9(4), pp. 371-386. (doi: 10.1093/ehjcvp/pvad025) (PMID:37019821) (PMCID:PMC10236521)

McGovern, J., Leadbitter, S., Miller, G., Hounat, A., Kamande, I., Dolan, R. D. , Horgan, P. G. , Chang, D. K. , Jamieson, N. B. and McMillan, D. C. (2023) The relationship between heart rate variability and TNM stage, co-morbidity, systemic inflammation and survival in patients with primary operable colorectal cancer. Scientific Reports, 13, 8157. (doi: 10.1038/s41598-023-35396-x) (PMID:37208421) (PMCID:PMC10198985)

Wood, C. S. et al. (2023) Spatially resolved transcriptomics deconvolutes prognostic histological subgroups in patients with colorectal cancer and synchronous liver metastases. Cancer Research, 83(8), pp. 1329-1344. (doi: 10.1158/0008-5472.CAN-22-2794) (PMID:37057593) (PMCID:PMC10102851)

Dreyer, S. B. et al. (2023) The impact of molecular subtyping on pathological staging of pancreatic cancer. Annals of Surgery, 277(2), e396-e405. (doi: 10.1097/SLA.0000000000005050) (PMID:36745763) (PMCID:PMC9831035)

2022

Ali, A. et al. (2022) Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. American Journal of Cancer Research, 12(12), pp. 5668-5683. (PMID:36628279) (PMCID:PMC9827095)

Fisher, N. C. et al. (2022) Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data. Clinical Cancer Research, 28(18), pp. 4056-4069. (doi: 10.1158/1078-0432.CCR-22-1102) (PMID:35792866) (PMCID:PMC9475248)

CHOLECOVID Collaborative, (2022) Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study). BJS Open, 6(3), zrac052. (doi: 10.1093/bjsopen/zrac052) (PMID:35511954) (PMCID:PMC9071082)

Izquierdo-Sanchez, L. et al. (2022) Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 76(5), pp. 1109-1121. (doi: 10.1016/j.jhep.2021.12.010) (PMID:35167909)

Dreyer, S. B., Upstill-Goddard, R., Legrini, A. , Biankin, A. V. , Jamieson, N. B. and Chang, D. K. (2022) Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence. Gastroenterology, 162(1), 320-324.e4. (doi: 10.1053/j.gastro.2021.09.022) (PMID:34534536) (PMCID:PMC8721486)

Dreyer, S., Upstill-Goddard, R., Legrini, A. , Biankin, A. , Jamieson, N. and Chang, D. (2022) Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. 15th World Congress of the International Hepato-Pancreato-Biliary Association, New York, USA, 30 Mar - 02 Apr 2022. S44-S45. (doi: 10.1016/j.hpb.2022.05.086)

2021

Gemenetzis, G., McKay, S., Pathak, S., Moir, J., Laing, R., Jamieson, N. B. , Young, A. L., Chatzizacharias, N. A., Giovinazzo, F. and Roberts, K. J. (2021) Surgical management of non-metastatic pancreatic cancer in the United Kingdom: results of a nationwide survey on current practice. Frontiers in Oncology, 11, 791946. (doi: 10.3389/fonc.2021.791946) (PMID:35004314) (PMCID:PMC8733562)

Pulvirenti, A. et al. (2021) Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors. Annals of Surgery, 274(6), pp. 1051-1057. (doi: 10.1097/SLA.0000000000003579) (PMID:31567347) (PMCID:PMC8557638)

Carotenuto, P. et al. (2021) Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 12, 6738. (doi: 10.1038/s41467-021-27099-6) (PMID:34795259) (PMCID:PMC8602334)

McKay, S. C. et al. (2021) Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. HPB, 23(11), pp. 1656-1665. (doi: 10.1016/j.hpb.2021.03.003) (PMID:34544628) (PMCID:PMC7973054)

Halle-Smith, J. M. et al. (2021) Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 47(9), pp. 2248-2255. (doi: 10.1016/j.ejso.2021.04.031) (PMID:34034941)

Lakis, V. et al. (2021) DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 4, 155. (doi: 10.1038/s42003-020-01469-0) (PMID:33536587) (PMCID:PMC7859232)

Jones, C. M. et al. (2021) Reply to comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic”. British Journal of Cancer, 124(3), pp. 679-680. (doi: 10.1038/s41416-020-01133-8) (PMID:33139799) (PMCID:PMC7851158)

Dreyer, S. B. et al. (2021) Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology, 160(1), pp. 362-377. (doi: 10.1053/j.gastro.2020.09.043) (PMID:33039466) (PMCID:PMC8167930)

Pea, A., Jamieson, N. B. and Braconi, C. (2021) Biology and clinical application of regulatory RNAs in hepatocellular carcinoma. Hepatology, 73(S1), pp. 38-48. (doi: 10.1002/hep.31225) (PMID:32160335)

2020

Moekotte, A. L. et al. (2020) Histopathologic predictors of survival and recurrence in resected ampullary adenocarcinoma. Annals of Surgery, 272(6), pp. 1086-1093. (doi: 10.1097/SLA.0000000000003177) (PMID:30628913)

Bailey, M. H. et al. (2020) Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nature Communications, 11, 4748. (doi: 10.1038/s41467-020-18151-y) (PMID:32958763) (PMCID:PMC7505971)

Jones, C. M. et al. (2020) Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. British Journal of Cancer, 123(5), pp. 709-713. (doi: 10.1038/s41416-020-0980-x) (PMID:32641867) (PMCID:PMC7341025)

Moekotte, A. L. et al. (2020) Development and external validation of a prediction model for survival in patients with resected ampullary adenocarcinoma. European Journal of Surgical Oncology, 46(9), pp. 1717-1726. (doi: 10.1016/j.ejso.2020.04.011) (PMID:32624291)

Li, C. H. et al. (2020) Sex differences in oncogenic mutational processes. Nature Communications, 11, 4330. (doi: 10.1038/s41467-020-17359-2) (PMID:32859912) (PMCID:PMC7455744)

Dreyer, S. B. et al. (2020) Precision oncology in surgery: patient selection for operable pancreatic cancer. Annals of Surgery, 272(2), pp. 366-376. (doi: 10.1097/SLA.0000000000003143) (PMID:32675551) (PMCID:PMC7373491)

Moekotte, A.L. et al. (2020) Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. British Journal of Surgery, 107(9), pp. 1171-1182. (doi: 10.1002/bjs.11555) (PMID:32259295)

Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31(6), 107625. (doi: 10.1016/j.celrep.2020.107625) (PMID:32402285)

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, et al. (2020) Pan-cancer analysis of whole genomes. Nature, 578(7793), pp. 82-93. (doi: 10.1038/s41586-020-1969-6) (PMID:32025007) (PMCID:PMC7025898)

Dreyer, S.B., Jamieson, N.B. , Cooke, S.L. , Valle, J.W., McKay, C.J., Biankin, A.V. and Chang, D.K. (2020) PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer. Clinical Oncology, 32(1), pp. 1-4. (doi: 10.1016/j.clon.2019.07.011) (PMID:31378449)

Dreyer, S.B., Jamieson, N.B. , Morton, J.P. , Sansom, O.J. , Biankin, A.V. and Chang, D.K. (2020) Pancreatic cancer: from genome discovery to PRECISION-Panc. Clinical Oncology, 32(1), pp. 5-8. (doi: 10.1016/j.clon.2019.08.007) (PMID:31522943)

RIFT Study Group, (2020) Evaluation of appendicitis risk prediction models in adults with suspected appendicitis. British Journal of Surgery, 107(1), pp. 73-86. (doi: 10.1002/bjs.11440) (PMID:31797357) (PMCID:PMC6972511)

2019

Vennin, C. et al. (2019) CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nature Communications, 10, 3637. (doi: 10.1038/s41467-019-10968-6) (PMID:31406163) (PMCID:PMC6691013)

Janssen, Q. P. et al. (2019) Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. Journal of the National Cancer Institute, 111(8), pp. 782-794. (doi: 10.1093/jnci/djz073) (PMID:31086963) (PMCID:PMC6695305)

Reader, C. S. et al. (2019) The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Journal of Pathology, 249(3), pp. 332-342. (doi: 10.1002/path.5320) (PMID:31259422) (PMCID:PMC6852434)

Seykora, T. F. et al. (2019) The beneficial effects of minimizing blood loss in pancreatoduodenectomy. Annals of Surgery, 270(1), pp. 147-157. (doi: 10.1097/SLA.0000000000002714) (PMID:29489483)

Dreyer, S. B. et al. (2019) Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chinese Clinical Oncology, 8(2), 16. (doi: 10.21037/cco.2019.04.06) (PMID:31070037)

Singh, G., Nahm, C. B., Jamieson, N. B. , Chua, T. C., Wong, S., Thoo, C., Mittal, A., Gill, A. J. and Samra, J. S. (2019) Management of post-pancreatectomy haemorrhage using resuscitative endovascular balloon occlusion of the aorta. Langenbeck's Archives of Surgery, 404(2), pp. 253-255. (doi: 10.1007/s00423-019-01759-0) (PMID:30758668)

Strijker, M., Chen, J.W., Mungroop, T.H., Jamieson, N.B. , van Eijck, C.H., Steyerberg, E.W., Wilmink, J.W., Groot Koerkamp, B., van Laarhoven, H.W. and Besselink, M.G. (2019) Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. British Journal of Surgery, 106(4), pp. 342-354. (doi: 10.1002/bjs.11111) (PMID:30758855)

Maggino, L. et al. (2019) Identification of an optimal cut-off for drain fluid amylase on postoperative day 1 for predicting clinically relevant fistula after distal pancreatectomy. Annals of Surgery, 269(2), pp. 337-343. (doi: 10.1097/SLA.0000000000002532) (PMID:28938266)

Nahm, C. B. et al. (2019) Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: a multi-institutional cohort study. European Journal of Surgical Oncology, 45(2), pp. 218-224. (doi: 10.1016/j.ejso.2018.10.050) (PMID:30348604)

Ecker, B. L. et al. (2019) Risk factors and mitigation strategies for pancreatic fistula after distal pancreatectomy. Annals of Surgery, 269(1), pp. 143-149. (doi: 10.1097/SLA.0000000000002491) (PMID:28857813)

2018

Ecker, B. L. et al. (2018) Characterization and optimal management of high-risk pancreatic anastomoses during pancreatoduodenectomy. Annals of Surgery, 267(4), pp. 608-616. (doi: 10.1097/SLA.0000000000002327) (PMID:28594741)

Dreyer, S.B., Jamieson, N.B. , Upstill-Goddard, R., Bailey, P.J. , McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V. and Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105(2), e183-e191. (doi: 10.1002/bjs.10772) (PMID:29341146) (PMCID:PMC5817249)

Ecker, B. L. et al. (2018) Pancreatogastrostomy vs. pancreatojejunostomy: a risk-stratified analysis of 5316 pancreatoduodenectomies. Journal of Gastrointestinal Surgery, 22(1), pp. 68-76. (doi: 10.1007/s11605-017-3547-2) (PMID:28840459)

2017

Balachandran, V. P. et al. (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 551, pp. 512-516. (doi: 10.1038/nature24462) (PMID:29132146) (PMCID:PMC6145146)

Scarpa, A. et al. (2017) Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 550(7677), p. 548. (doi: 10.1038/nature24026) (PMID:28953865)

Grose, D. et al. (2017) The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 8(4), pp. 683-695. (doi: 10.21037/jgo.2017.04.01) (PMID:28890819) (PMCID:PMC5582039)

McMillan, M. T. et al. (2017) Incorporation of procedure-specific risk into the ACS-NSQIP surgical risk calculator improves the prediction of morbidity and mortality after pancreatoduodenectomy. Annals of Surgery, 265(5), pp. 978-986. (doi: 10.1097/SLA.0000000000001796) (PMID:27232260)

Johns, A. L. et al. (2017) Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Medicine, 9, 41. (doi: 10.1186/s13073-017-0430-4) (PMID:28454591) (PMCID:PMC5408494)

Scarpa, A. et al. (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 543(7643), pp. 65-71. (doi: 10.1038/nature21063) (PMID:28199314)

Jamieson, N.B. and Maker, A.V. (2017) Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Therapy, 24(3), pp. 134-140. (doi: 10.1038/cgt.2016.63) (PMID:27834354)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi: 10.1053/j.gastro.2016.09.060) (PMID:27856273)

2016

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29(6), pp. 832-845. (doi: 10.1016/j.ccell.2016.04.014) (PMID:27265504) (PMCID:PMC4912354)

Jabbar, S.A.A., Jamieson, N.B. , Morris, A.J., Oien, K.A. , Duthie, F., McKay, C.J., Carter, C.R. and Dickson, E.J. (2016) A Glasgow tipple-transjugular intrahepatic portosystemic shunt insertion prior to Whipple resection. Journal of Surgical Case Reports, 2016(5), rjw089. (doi: 10.1093/jscr/rjw089) (PMID:27177892) (PMCID:PMC4866079)

Palani Velu, L.K., McKay, C.J., Carter, C.R., McMillan, D.C. , Jamieson, N.B. and Dickson, E.J. (2016) Serum amylase and C-reactive protein in risk stratification of pancreas-specific complications after pancreaticoduodenectomy. British Journal of Surgery, 103(5), pp. 553-563. (doi: 10.1002/bjs.10098) (PMID:26898605)

Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi: 10.1038/nature16965) (PMID:26909576)

Gingras, M.-C. et al. (2016) Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Reports, 14(4), pp. 907-919. (doi: 10.1016/j.celrep.2015.12.005) (PMID:26804919) (PMCID:PMC4982376)

Ali, A. et al. (2016) Investigating various thresholds as immunohistochemistry cutoffs for observer agreement. Applied Immunohistochemistry and Molecular Morphology, 25(9), pp. 599-608. (doi: 10.1097/PAI.0000000000000357) (PMID:27093449)

2015

Palani Velu, L., Chandrabalan, V., McMillan, D. , McKay, C., Carter, C. R., Jamieson, N. and Dickson, E. (2015) Routine drainage after pancreaticoduodenectomy. Annals of Surgery, 262(6), e107. (doi: 10.1097/sla.0000000000000758) (PMID:24887980)

Jamieson, N. B. , Chang, D. K. and Biankin, A. V. (2015) Cancer genetics and implications for clinical management. Surgical Clinics of North America, 95(5), pp. 919-934. (doi: 10.1016/j.suc.2015.05.003) (PMID:26315514)

Graham, J., Jamieson, N.B. , Rulach, R., Grimmond, S.M., Chang, D.K. and Biankin, A.V. (2015) Pancreatic cancer genomics: where can the science take us? Clinical Genetics, 88(3), pp. 213-219. (doi: 10.1111/cge.12536) (PMID:25388820)

Palani Velu, L. K., Steele, C. W. , Dickson, E., Carter, C. R., McKay, C. J., Horgan, P. G. , McMillan, D. C. and Jamieson, N. B. (2015) RE:nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Journal of the National Cancer Institute, 107(9), djv204. (doi: 10.1093/jnci/djv204) (PMID:26251329)

Frampton, A. E. et al. (2015) microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. European Journal of Cancer, 51(11), pp. 1389-1404. (doi: 10.1016/j.ejca.2015.04.006) (PMID:26002251)

McGlynn, L. M., McCluney, S., Jamieson, N. B. , Thomson, J., MacDonald, A. I., Oien, K. , Dickson, E. J., Carter, C. R., McKay, C. J. and Shiels, P. G. (2015) SIRT3 & SIRT7: potential novel biomarkers for determining outcome in pancreatic cancer patients. PLoS ONE, 10(6), e0131344. (doi: 10.1371/journal.pone.0131344) (PMID:26121130) (PMCID:PMC4487247)

Solaini, L., Jamieson, N.B. , Metcalfe, M., Abu Hilal, M., Soonawalla, Z., Davidson, B.R., McKay, C. and Kocher, H.M. (2015) Outcome after surgical resection for duodenal adenocarcinoma in the UK. British Journal of Surgery, 102(6), pp. 676-681. (doi: 10.1002/bjs.9791) (PMID:25776995)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi: 10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

Maker, A. V., Carrara, S., Jamieson, N. B. , Pelaez-Luna, M., Lennon, A. M., Dal Molin, M., Scarpa, A., Frulloni, L. and Brugge, W. R. (2015) Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: A critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. Journal of the American College of Surgeons, 220(2), pp. 243-253. (doi: 10.1016/j.jamcollsurg.2014.11.001) (PMID:25592469) (PMCID:PMC4304635)

Rainero, E., Howe, J. D., Caswell, P. T., Jamieson, N. B. , Anderson, K., Critchley, D. R., Machesky, L. and Norman, J. C. (2015) Ligand-occupied integrin internalization links nutrient signaling to invasive migration. Cell Reports, 10(3), pp. 398-413. (doi: 10.1016/j.celrep.2014.12.037)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi: 10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

2014

Lunardi, S. et al. (2014) IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget, 5(22), pp. 11064-11080. (doi: 10.18632/oncotarget.2519) (PMID:25415223) (PMCID:PMC4294325)

Steele, C. W., Jamieson, N. B. and Carter, C. R. (2014) Inflammatory dysregulation and cancer: From molecular mechanisms to therapeutic opportunities. In: Wondrak, G. T. (ed.) Stress Response Pathways in Cancer. Springer, pp. 375-395. ISBN 9789401794206 (doi: 10.1007/978-94-017-9421-3_17)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi: 10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Hamilton, G. et al. (2014) AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget, 5(15), pp. 6142-6167. (doi: 10.18632/oncotarget.2178) (PMID:25071014) (PMCID:PMC4171619)

Palani Velu, L. K., Chandrabalan, V. V., Jabbar, S., McMillan, D. C. , McKay, C. J., Carter, C. R., Jamieson, N. B. and Dickson, E. J. (2014) Serum amylase on the night of surgery predicts clinically significant pancreatic fistula after pancreaticoduodenectomy. HPB, 16(7), pp. 610-619. (doi: 10.1111/hpb.12184) (PMID:24246024)

Jamieson, N. B. , Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Can we move towards personalised pancreatic cancer therapy? Expert Review of Gastroenterology and Hepatology, 8(4), pp. 335-338. (doi: 10.1586/17474124.2014.893820) (PMID:24702631)

Li, A. et al. (2014) Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology, 146(5), 1386-1396.e17. (doi: 10.1053/j.gastro.2014.01.046) (PMID:24462734) (PMCID:PMC4000441)

Frampton, A. E., Giovannetti, E., Jamieson, N. B. , Krell, J., Gall, T. M.H., Stebbing, J., Jiao, L. R. and Castellano, L. (2014) A microRNA meta-signature for pancreatic ductal adenocarcinoma. Expert Review of Molecular Diagnostics, 14(3), pp. 267-271. (doi: 10.1586/14737159.2014.893192)

Roxburgh, C.S. et al. (2014) A national survey of attitudes to research in Scottish General Surgery Trainees. Scottish Medical Journal, 59(1), pp. 9-15. (doi: 10.1177/0036933013518142) (PMID:24434857)

Ali, A. et al. (2014) Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clinical Pathology, 14, p. 35. (doi: 10.1186/1472-6890-14-35)

Chang, D. K. , Jamieson, N. B. , Grimmond, S. M. and Biankin, A. V. (2014) Stratified medicine for pancreatic cancer. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Elsevier, pp. 807-814. ISBN 9780123868824 (doi: 10.1016/B978-0-12-386882-4.00034-7)

Jamieson, N. B. , Grimmond, S. M., Biankin, A. V. and Chang, D. K. (2014) Pancreatic cancer: Challenges for therapeutic development. In: Scarlett, C. J. and Vuong, Q. V. (eds.) Plant Bioactive Compounds for Pancreatic Cancer Prevention and Treatment. Nova Science, pp. 1-28. ISBN 9781634633246

2013

Chang, D. K. , Jamieson, N. B. , Scarpa, A., McKay, C. J. and Biankin, A. V. (2013) Reply to G.F. Arroyo. Journal of Clinical Oncology, 31(30), pp. 3843-3844. (doi: 10.1200/JCO.2013.51.3176) (PMID:24043730)

Denley, S.M., Jamieson, N.B. , McCall, P., Oien, K.C.S. , Morton, J.P. , Carter, C.R., Edwards, J. and McKay, C.J. (2013) Activation of the IL-6R/Jak/Stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery, 17(5), pp. 887-898. (doi: 10.1007/s11605-013-2168-7)

Chang, D.K. et al. (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Journal of Clinical Oncology, 31(10), pp. 1348-1356. (doi: 10.1200/JCO.2012.46.8868) (PMID:23439753)

Steele, C.W., Jamieson, N.B. , Evans, T.R.J. , McKay, C.J., Sansom, O.J. , Morton, J. and Carter, C.R. (2013) Exploiting inflammation for therapeutic gain in pancreatic cancer. British Journal of Cancer, 108(5), pp. 997-1003. (doi: 10.1038/bjc.2013.24)

Jamieson, N.B. , Chan, N.I.J., Foulis, A.K., Dickson, E.J., McKay, C.J. and Carter, C.R. (2013) The prognostic influence of resection margin clearance following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery, (doi: 10.1007/s11605-012-2131-z)

2012

Jamieson, N.B. , Mohamed, M., Oien, K.A. , Foulis, A.K., Dickson, E.J., Imrie, C.W., Carter, C.R., McKay, C.J. and McMillan, D.C. (2012) The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 19(11), pp. 3581-3590. (doi: 10.1245/s10434-012-2370-y)

Dozynkiewicz, M.A. et al. (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Developmental Cell, 22(1), pp. 131-145. (doi: 10.1016/j.devcel.2011.11.008)

Jamieson, N. B. , Morran, D. C., Morton, J. P., Ali, A., Dickson, E. J., Carter, C. R., Sansom, O. J. , Evans, T. R. J. , McKay, C. J. and Oien, K. A. (2012) MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clinical Cancer Research, 18(2), pp. 534-545. (doi: 10.1158/1078-0432.CCR-11-0679)

2011

Steele, C.W., Oien, K.A. , McKay, C.J. and Jamieson, N.B. (2011) Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Pancreas, 40(8), pp. 1165-1171. (doi: 10.1097/MPA.0b013e3182218ffb)

Kennedy, A.l. et al. (2011) Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis. Molecular Cell, 42(1), pp. 36-49. (doi: 10.1016/j.molcel.2011.02.020)

Jamieson, N.B., Foulis, A.K., Oien, K.A. , Dickson, E.J., Imrie, C.W., Carter, R. and McKay, C.J. (2011) Peripancreatic Fat Invasion Is an Independent Predictor of Poor Outcome Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 15(3), pp. 512-524. (doi: 10.1007/s11605-010-1395-4)

Jamieson, N.B., Carter, C.R., McKay, C.J. and Oien, K.O. (2011) Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. Clinical Cancer Research, 17(10), pp. 3316-3331. (doi: 10.1158/1078-0432.CCR-10-3284)

Jamieson, N.B., Denley, S.M., Logue, J., MacKenzie, D.J., Foulis, A.K., Dickson, E.J., Imrie, C.W., Carter, R., McKay, C.J. and McMillan, D.J. (2011) A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 18(8), pp. 2318-2328. (doi: 10.1245/s10434-011-1560-3)

2010

Chandrabalan, V. et al. (2010) Preoperative determinants of the length of hospital stay in patients undergoing surgery for pancreatic cancer. Pancreas, 39(8), p. 1313. (doi: 10.1097/MPA.0b013e3181f73ec0)

Morton, J.P. et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(1), pp. 246-251. (doi: 10.1073/pnas.0908428107)

Jamieson, N. B., Foulis, A. K., Oien, K. A. , Going, J. J., Glen, P., Dickson, E. J., Imrie, C. W., McKay, C. J. and Carter, R. (2010) Positive Mobilization Margins Alone Do Not Influence Survival Following Pancreatico-Duodenectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 251(6), pp. 1003-1010. (doi: 10.1097/SLA.0b013e3181d77369)

Lafferty-Whyte, K. et al. (2010) Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics, 11(1), p. 532. (doi: 10.1186/1471-2164-11-532)

Morton, J. et al. (2010) LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology, 139(2), 586-597.e6. (doi: 10.1053/j.gastro.2010.04.055)

Morton, J.P. et al. (2010) Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 139(1), pp. 292-303. (doi: 10.1053/j.gastro.2010.03.034)

Nitsche, C. J., Jamieson, N., Lerch, M. M. and Mayerle, J. V. (2010) Drug induced pancreatitis. Best Practice and Research: Clinical Gastroenterology, 24(2), pp. 143-155. (doi: 10.1016/j.bpg.2010.02.002)

2009

Lafferty-Whyte, K., Cairney, C.J., Jamieson, N., Oien, K.A. and Keith, W.N. (2009) Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms. Biochimica et Biophysica Acta: Molecular Basis of Disease, 1792(4), pp. 341-352. (doi: 10.1016/j.bbadis.2009.02.003)

2008

Robertson, E., Austin, D., Jamieson, N. and Hogg, K. (2008) Balsalazide-induced myocarditis. International Journal of Cardiology, 130(3), E121-E122.

2006

Glen, P., Jamieson, N.B., McMillan, D.C., Carter, R., Imrie, C.W. and Mckay, C.J. (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology, 6(5), pp. 450-453. (doi: 10.1159/000094562)

2005

Jamieson, N.B., Glen, P., McMillan, D.C. , McKay, C.J., Foulis, A.K., Carter, R. and Imrie, C.W. (2005) Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. British Journal of Cancer, 92(1), pp. 21-23. (doi: 10.1038/sj.bjc.6602305)

Singhal, A., Jamieson, N.B., Fewtrell, M., Deanfield, J., Lucas, A. and Sattar, N. (2005) Adiponectin predicts insulin resistance but not endothelial function in young, healthy adolescents. Journal of Clinical Endocrinology and Metabolism, 90(8), pp. 4615-4621. (doi: 10.1210/jc.2005-0131)

2004

Jamieson, N.B., Brown, D.J.F., Wallace, A.M. and McMillan, D.C. (2004) Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer. Cytokine, 27(2-3), pp. 90-92. (doi: 10.1016/j.cyto.2004.03.017)

2003

Jamieson, N.B., McMillan, D.C. , Brown, D.J.F. and Wallace, A.M. (2003) Comparison of simple acid-ethanol precipitation with gel exclusion chromatography for measuring leptin binding in serum of normal subjects and cancer patients. Annals of Clinical Biochemistry, 40(2), pp. 185-187. (doi: 10.1258/000456303763046157)

Ramsay, J.E., Jamieson, N.B., Greer, I.A. and Sattar, N. (2003) Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension, 42(5), pp. 891-894. (doi: 10.1161/01.HYP.0000095981.92542.F6)

This list was generated on Mon Nov 18 14:41:53 2024 GMT.

Jump to: Articles | Book Sections | Conference or Workshop Item

Number of items: 123.

Articles

Haddad, T. S. et al. (2023) Pseudobudding: ruptured glands do not represent true tumor buds. Journal of Pathology, 261(1), pp. 19-27. (doi: 10.1002/path.6146) (PMID:37403270)

Li, C. H. et al. (2020) Sex differences in oncogenic mutational processes. Nature Communications, 11, 4330. (doi: 10.1038/s41467-020-17359-2) (PMID:32859912) (PMCID:PMC7455744)

Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31(6), 107625. (doi: 10.1016/j.celrep.2020.107625) (PMID:32402285)

Seykora, T. F. et al. (2019) The beneficial effects of minimizing blood loss in pancreatoduodenectomy. Annals of Surgery, 270(1), pp. 147-157. (doi: 10.1097/SLA.0000000000002714) (PMID:29489483)

Scarpa, A. et al. (2017) Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 550(7677), p. 548. (doi: 10.1038/nature24026) (PMID:28953865)

Scarpa, A. et al. (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 543(7643), pp. 65-71. (doi: 10.1038/nature21063) (PMID:28199314)

Jamieson, N.B. and Maker, A.V. (2017) Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Therapy, 24(3), pp. 134-140. (doi: 10.1038/cgt.2016.63) (PMID:27834354)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi: 10.1053/j.gastro.2016.09.060) (PMID:27856273)

Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi: 10.1038/nature16965) (PMID:26909576)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi: 10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi: 10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Robertson, E., Austin, D., Jamieson, N. and Hogg, K. (2008) Balsalazide-induced myocarditis. International Journal of Cardiology, 130(3), E121-E122.

Book Sections

Conference or Workshop Item

This list was generated on Mon Nov 18 14:41:53 2024 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

A Molecular and Spatial-temporal Topographical Atlas Defining Cell State Interactions to Inform Resistance to Treatment and Understand Prognosis in Pancreatic Cancer
Pancreatic Cancer UK
2024 - 2025
Multi-scale multi-modal characterisation of pre-malignant pancreatic lesions to define targets for early intervention
Pancreatic Cancer UK
2024 - 2027
The use of multi modal spatial strategies to characterise pre malignant pancreatic lesions and identify targets for early diagnosis of pancreatic cancer
Office of the Chief Scientific Adviser
2024 - 2027
Single cell spatial transcriptomics to investigate colorectal adenoma immune contexture and its association with future polyp or cancer risk in bowel screening patients
Guts UK Charity
2024 - 2025
Early Detection of Pancreatic Cancer
NHS Greater Glasgow and Clyde Endowment Funds
2023 - 2025
IL6/JAK/STAT3 pathway in colorectal cancer
Office of the Chief Scientific Adviser
2023 - 2025
Grand Challenges
Beatson Cancer Charity
2023 - 2025
In-situ transcriptomic and proteomic subcellular molecular imager
Medical Research Council
2022 - 2023
Integrated analysis from mouse to man for Early detection of Mesothelioma.
Cancer Research UK
2022 - 2027
AI-Pancreas - Integrating spatial multi-omics
Medical Research Council
2022 - 2023
Understanding the role of N4-acetylcytidine in the progression of aggressive cancer
Wellcome Trust
2022 - 2022
The role of tumour microenvironment heterogeneity in determining metastatic patterns in Pancreatic and Oesophagogastric Adenocarcinoma
Rosetrees Trust
2022 - 2024
Pancreatic Cystic Lesions: Spatial Transcriptomics
Medical Research Council
2021 - 2024
Generation of a unique Glasgow RadNet multimodality molecular imaging dataset measuring dynamic immunometabolic phenotypes during radiotherapy in mouse models of lung cancer
Cancer Research UK
2021 - 2022
Support for Pancreatic Cancer research
NHS Greater Glasgow and Clyde Endowment Funds
2020 - 2022
Combination Therapies Targeting Immune Evasion in Pancreatic Cancer
Cancer Research UK
2018 - 2023
Using preoperative pancreatic endoscopic ultrasound to enable precision medicine for the management of pancreatic cancer
Pancreatic Cancer Research Fund
2015 - 2017
NcRNA Biomarkers In Pancreaticobiliary Malignancy - Implications For Therapy
Academy of Medical Sciences
2014 - 2015

Supervision

Kamdar, Anna
Transcriptomics of Small Vessel Disease

Research datasets

Jump to: 2022

Number of items: 1.

2022

ROSS, K. , Keith, N. , Abbott, L., Adams, C., Aitken, E., Aslett, O., Basra, S., Bell, I., Bradley, J., Brown, T., Brown, W., Chen, R., Cheskin, L., Corrie, R., de Vries, E., Defty, E., Drake, H., Dunlop, H., Emadi, A. , Evans, J. , Everett, S., Feng, Z., Fraser, A., Gallacher, K. , Gaynor-Kirk, E., Halsey, C. , Harris, F., Hu, J., Hush, G., Jamieson, N. , Jameison, V., Jones, R. , Just, L., Lembo, T. , Lloyd, B., Ma, C.-L., Macdonald, S. , Mathias, M. , McAra, M., McCaffrey, B., Mccluskey, L.-A., Mchattie, L.-S., Mcneill, E., Milliken, A., Mogford, D., Morris, G., Nicoll, M., O'Brien, T., Onwuka, T., Papanastasatou, M., Perry, M. , Prosser, Z., Proudfoot, B., Raman Komnedath, S., Robinson, J. , Sleight, R., Smith, P., Stricevic, M., Tharp, B., Thoresson, V., Thorne, J., Vansteenhouse, H., Welisch, G. and Wu, O. (2022) Symbiotic Futures: Health, Well-being and Care in the Post-Covid World. [Data Collection]

This list was generated on Mon Nov 18 23:20:10 2024 GMT.

We use cookies

Necessary cookies

Analytics cookies

Clarity

Professor Nigel Jamieson

Biography

Research interests

Research groups

Publications

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2006

2005

2004

2003

Articles

Book Sections

Conference or Workshop Item

Grants

Supervision

Research datasets

2022